Asia On The Move: Takeda Hires Merck Exec To Lead European Business
This article was originally published in PharmAsia News
One in and one out at Takeda’s European and Canada business unit while J&J appoints an outsider to head its consumer health business in Japan. Personnel changes also take place at Xinrong Best Medical Instrument following significant investment from Blackstone.
You may also be interested in...
From requiring early notification to whole-process involvement, China is clearing a path for a far-reaching new biosecurity law, which if implemented will pose high hurdles for international firms planning to conduct clinical studies in the country, industry observers say.
In a bipartisan move, the US Senate is moving to impose new rules on companies - including those from China - seeking US initial public offerings, adding further uncertainty over such plans and further stoking trade tensions.
Developing some of the first coronavirus vaccines and antibody testing kits, venture-backed firms in China have responded fast and partnered actively in the fight against the pandemic, helping them to raise new funds and reach deals. But there have been cautionary tales in other sectors and some investors remain wary.